Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 19, 2024

Overall Survival and Exploratory Biomarker Analysis Results for Abemaciclib + Trastuzumab ± Fulvestrant vs Trastuzumab + Chemotherapy in Patients With HR+, HER2+ MBC

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients
Clin. Cancer Res 2024 Jan 05;30(1)39-49, SM Tolaney, S Goel, J Nadal, H Denys, MR Borrego, LM Litchfield, J Liu, AK Appiah, Y Chen, F André

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading